Quanterix (QTRX) CFO reports RSU vesting and tax-withholding share dispositions
Quanterix CFO Vandana Sriram reported routine equity compensation activity involving Restricted Stock Units (RSUs). On May 15, 2026, RSUs converted into common stock in several tranches, and shares were disposed of to cover tax obligations. Following these transactions, the CFO directly held 28,897 shares of Quanterix common stock.
Quanterix (QTRX) CTO gains 1,558 shares from RSU vesting, 467 withheld for tax
Quanterix Corp's Chief Technology Officer, Michael Francis Miller, received 1,558 shares of common stock on May 15, 2026, due to the vesting of restricted stock units. Concurrently, 467 shares were withheld at $2.75 per share to cover tax obligations. Following these transactions, Miller directly owns 32,694 common shares and 760 restricted stock units.
Quanterix Corp stock (US74876Y1001): Analyst price target raised while shares trade near lows
Quanterix Corp (QTRX) stock is trading near its recent lows despite an analyst raising its price target to 7.40 USD, an 11.5% increase, according to a January 2026 update. The company specializes in ultra-sensitive protein detection technologies, crucial for pharmaceutical research and diagnostics, particularly in neurodegeneration and oncology. The gap between the current share price of 2.75 USD and the analyst target highlights the speculative nature of this small-cap healthcare stock, compelling investors to weigh execution risks against the potential of its innovative technology.
Portolan Capital, George McCabe report 6.25% stake in Quanterix (QTRX)
Portolan Capital Management, LLC and George McCabe have reported a beneficial ownership of 2,945,823 shares of Quanterix Common Stock (QTRX), which represents a 6.25% stake in the company. This disclosure was made via an amended Schedule 13G/A filing with the SEC. Both entities hold sole voting and dispositive power over these shares, indicating a passive investment intent.
Quanterix (NASDAQ: QTRX) — Ameriprise reports 3,542,374 shared votes
Ameriprise Financial, Inc. has filed an amended Schedule 13G/A, reporting shared voting and dispositive power over 3,542,374 shares of Quanterix Corp (NASDAQ: QTRX) common stock, which represents 7.5% of the class. Despite this, Ameriprise explicitly disclaims beneficial ownership of these shares, signaling institutional involvement through shared authority rather than direct ownership. This filing serves as an update to their previous 13G disclosures, providing transparency on their passive stake and control rights.
Quanterix (QTRX) CFO Vandana Sriram to depart in June 2026 after planned transition
Quanterix (QTRX) announced that CFO Vandana Sriram will depart on June 15, 2026, after a planned transition period. She will remain active until then to ensure a smooth handover while the company searches for a successor with an executive search firm. Quanterix stated that her departure is not due to any disagreements regarding accounting practices, financial statements, internal controls, or operations, emphasizing the company's solid financial footing and focus on cash flow breakeven.
Quanterix (QTRX) price target decreased by 33.33% to 4.42
This article reports a significant 33.33% decrease in the price target for Quanterix (QTRX), bringing it down to $4.42. The news suggests a potentially negative outlook or revised valuation for the company's stock from the perspective of analysts or the source of this price target change.
Quanterix stock (US74876Y1001): Biotech diagnostics firm faces headwinds amid guidance revision
Quanterix Corp (QTRX) has seen its stock decline over 54% year-to-date in 2026 amidst revenue challenges, despite maintaining FY2026 guidance of $169–$174 million. The company, which specializes in ultra-sensitive digital immunoassay platforms, faces investor concerns regarding growth sustainability and competitive pressures. Analysts currently have a "Reduce" consensus rating for QTRX, with a price target of $4.00.
Quanterix CFO Vandana Sriram to depart in June
Quanterix Corporation announced that its Chief Financial Officer, Vandana Sriram, will leave the company on June 15, 2026. This departure comes as the company's stock has seen a significant decline year-to-date. Despite the stock performance, Quanterix maintains a strong current ratio and holds more cash than debt, though it faces negative free cash flow.
Quanterix CFO Michael J. Doyle to Depart on July 3, 2026; Search for Successor Begins
Quanterix Corporation has announced that its Chief Financial Officer, Michael J. Doyle, will depart on July 3, 2026. The company has initiated a formal search process to find his successor, and Doyle will remain in his role until his departure date to ensure a smooth transition. An update will be provided once a new CFO is appointed.
Quanterix finance chief to depart after June 15 handover
Quanterix Corporation announced that its Chief Financial Officer, Vandana Sriram, will be departing the company on June 15, 2026. A search for her successor is currently underway. CEO Everett Cunningham thanked Ms. Sriram for her significant contributions to the company's financial evolution, cost discipline, and cash management.
Quanterix Corporation (NASDAQ:QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation reported its Q1 2026 earnings, exceeding EPS expectations, and discussed strategic shifts and investments. President and CEO Everett Cunningham outlined plans to strengthen the research tools business, accelerate growth in Alzheimer's diagnostics, and enhance commercial effectiveness. The company aims for cash flow breakeven by Q4 2026 and highlighted new hires, product roadmap streamlining, and key partnerships like the one with Tempus AI.
Quanterix (QTRX) Q1 Loss Of US$0.37 Per Share Reinforces Bearish Profitability Concerns
Quanterix (QTRX) reported a Q1 2026 revenue of US$36.4 million and a basic EPS loss of US$0.37, maintaining its loss-making status with a trailing twelve-month basic EPS loss of US$2.33. The company's persistent losses, which have been rising over the past five years and are forecast to continue, raise concerns among investors despite modest revenue growth. The stock trades at a significantly lower Price-to-Sales ratio compared to its peers, reflecting market skepticism about its path to profitability.
QTRX Maintained by TD Cowen -- Price Target Lowered to $4.00
TD Cowen analyst Dan Brennan maintained a "Hold" rating for Quanterix (QTRX) but significantly lowered the price target from $7.00 to $4.00, reflecting a cautious outlook. Despite a substantial undervaluation according to GuruFocus's GF Value™ at $13.17 against a current price of $2.75, the stock is flagged as a "Possible Value Trap" due to low profitability. Quanterix, a life sciences company specializing in biomarker breakthroughs, shows moderate potential for long-term returns with a GF Score™ of 66, driven by strong growth and financial strength but hampered by low profitability and valuation.
QUANTERIX ($QTRX) Releases Q1 2026 Earnings, Stock Rises
QUANTERIX ($QTRX) announced its Q1 2026 earnings, reporting -$0.39 per share, which beat analyst estimates of -$0.55. However, the company's revenue of $36.42 million missed estimates. Following the announcement, the stock price rose by 1.82%.
Quanterix keeps 2026 outlook, eyes FDA decision on Alzheimer’s test
Quanterix Corporation reported Q1 2026 revenues of $36.4 million, a 20% increase year-over-year, and reaffirmed its full-year 2026 revenue guidance of $169 to $174 million. The company is actively working towards cash flow breakeven in the second half of the year, focusing on commercial effectiveness and expecting key milestones in its Alzheimer's diagnostics business, including an FDA decision on its 510(k) application. Quanterix also highlighted strategic collaborations and product advancements in biomarker detection.
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
Quanterix Corporation (QTRX) reported a Q1 loss of $0.39 per share, missing the Zacks Consensus Estimate of a $0.31 loss and its own revenue estimates at $36.42 million. The company has underperformed the market this year, with its shares losing 48.1% while the S&P 500 gained 6%. Given these results and an unfavorable estimate revision trend, Quanterix currently holds a Zacks Rank #4 (Sell), suggesting potential underperformance in the near future.
Quanterix (NASDAQ: QTRX) grows Q1 revenue 20% and keeps 2026 outlook
Quanterix (NASDAQ: QTRX) reported a 20% increase in Q1 2026 revenue to $36.4 million, driven by growth in its Simoa and spatial biology platforms. Despite a GAAP net loss, the company improved its adjusted gross margin and reduced its adjusted EBITDA loss. Quanterix reaffirmed its full-year 2026 revenue guidance of $169–$174 million and expects to achieve cash flow breakeven in the second half of 2026, supported by $85 million in cost synergies from the Akoya Biosciences integration.
Quanterix partners with Tempus AI on Alzheimer’s blood test
Quanterix Corporation announced a collaboration with Tempus AI Inc. to expand access to blood-based biomarker testing for Alzheimer’s disease. Tempus AI will develop a care gap program, making Quanterix's LucentAD Complete multi-biomarker blood test available through its clinical ordering platform. This initiative aims to integrate Alzheimer's biomarker testing into routine clinical practice and identify patients who could benefit from early evaluation.
Quanterix Corporation Announces Date of 2026 Annual Meeting
Quanterix Corporation (QTRX) has announced the date of its 2026 Annual Meeting. The announcement was delivered via Quantisnow, a real-time market data and news platform for retail investors. This platform aggregates various financial data, including SEC filings, analyst ratings, and press releases.
Press Release: Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Quanterix Corporation plans to release its first-quarter 2026 financial results after the market closes on Monday, May 6, 2026. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. A replay will be available on the Quanterix website after the event.
QTRX: Alzheimer’s Blood Test Progress Will Support Long Term Upside Potential
Analysts have revised Quanterix's (QTRX) price target down by $2, reflecting updated assumptions for fair value, discount rate, revenue growth, and profit margin. Despite this, bullish analysts see long-term upside potential, especially with recent positive developments like the FDA submission for an Alzheimer's blood test and new immunoassay technologies. Bearish views highlight risks related to cash flow and the materialization of profitability, suggesting a cautious approach until consistent execution is demonstrated.
Quanterix (QTRX) COO logs RSU conversion and small tax share disposal
Quanterix Corp's Chief Operating Officer, Michael Francis Miller, reported routine equity compensation activity, exercising 130 restricted stock units (RSUs) which converted into 130 common shares. To cover tax obligations, 39 shares were disposed of through a tax-withholding transaction. Following these transactions, Miller directly holds 32,613 common shares and 549 outstanding RSUs.
Quanterix (QTRX) price target decreased by 13.33% to 6.63
The article reports that Quanterix (QTRX) has experienced a 13.33% decrease in its price target, bringing it down to $6.63. This information is based on recent analyst coverage.
Quanterix to Report First Quarter 2026 Financial Results on May 6, 2026
Quanterix Corporation announced it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T. to discuss its first quarter 2026 financial results. The company will issue a press release with these results prior to the call. Interested investors can access the details via a toll-free number or a live webcast on the Quanterix website.
Quanterix schedules after-close Q1 results, 4:30 p.m. ET call
Quanterix Corporation (Nasdaq: QTRX) announced it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T. to discuss its first-quarter 2026 financial results. The company will issue a press release with these results after the market closes on the same day. Interested parties can access the call via a toll-free number or a live webcast on the Quanterix investor relations website.
[ARS] Quanterix Corp SEC Filing
This article announces an ARS SEC filing by Quanterix Corp (QTRX) on April 24, 2026, accessible as a PDF document. It also provides an overview of Quanterix stock data, recent news, and other SEC filings, such as their upcoming first-quarter 2026 financial report and information on insider trading activity.
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
Quanterix Corporation announced it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. The company will issue a press release with these results before the market opens on the same day. Interested parties can access the call via phone or live webcast, with an archived replay available for one year.
How many employees work at Quanterix?
Quanterix Corp. currently has 475 employees, a decrease of 38.4% year-over-year, according to Revelio Labs data updated in December 2025. The company specializes in digitizing biomarker analysis with its ultra-sensitive detection solution, Simoa, aiming to advance precision health. Quanterix was established in 2007 and is located in Billerica, Massachusetts.
Quanterix Is Maintained at Hold by Canaccord Genuity
Canaccord Genuity has reiterated its 'Hold' rating on Quanterix, indicating a maintained stance on the company's stock. This suggests that the analyst firm views Quanterix as appropriately valued or sees no immediate catalysts for a significant price movement in either direction. Investors and market watchers should note that a "Hold" rating typically implies that analysts advise current shareholders to retain their positions rather than buying more or selling.
Quanterix Corp stock (US74876Y1001): Is its ultra-sensitive protein detection tech strong enough to unlock diagnostics upside?
This report analyzes Quanterix Corp's stock, focusing on its pioneering Simoa technology for ultra-sensitive protein detection. It outlines the company's business model, market relevance for U.S. investors in precision medicine, and growth drivers, particularly in neurodegenerative disease research. The article also addresses analyst views, potential risks, and investment considerations for the company's future.
Quanterix unveils Content Innovation Engine at AACR 2026
Quanterix Corporation is launching its new Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. This engine integrates Akoya Biosciences' spatial biology platform with Quanterix's ultra-sensitive immunoassay development using SIMOA technology, providing a biology-first approach to cancer research. Quanterix will also introduce new offerings like the IO60 Spike-In Module for checkpoint therapy and tertiary lymphoid structure markers, and the PhenoCode Molecular Barcoding Kit for antibody barcoding.
Wall Street Zen Downgrades Quanterix (NASDAQ:QTRX) to Sell
Wall Street Zen has downgraded Quanterix (NASDAQ:QTRX) from a "hold" to a "sell" rating, contributing to a "Reduce" consensus rating and an average price target of $8.00. The company recently missed quarterly EPS estimates but exceeded revenue expectations, remaining unprofitable with a forecasted negative EPS for the current fiscal year. Despite the downgrade, institutional investors hold a significant portion of the stock, and several large funds increased their stakes in the last quarter.
Quanterix (QTRX) COO exercises 1,558 RSUs; 467 shares withheld for taxes
Quanterix COO Michael Francis Miller exercised 1,558 Restricted Stock Units (RSUs) into common stock on April 15, 2026. To cover tax obligations from these vesting events, 467 shares were withheld and disposed of at $3.60 per share. Following these transactions, Miller directly holds 32,522 shares of Quanterix common stock.
Quanterix (NASDAQ: QTRX) CFO nets shares after RSU vesting and tax withholding
Quanterix (NASDAQ: QTRX) CFO Sriram Vandana received shares through the vesting of restricted stock units (RSUs) on April 15, 2026. A total of 1,833 shares across three tranches converted into common stock, with a portion withheld for tax obligations rather than being sold in the open market. Following these transactions, the CFO directly holds 28,713 shares of Quanterix common stock.
Quanterix (QTRX) Launches AidaBREAST Assay for Breast Cancer Predictions
Quanterix (QTRX) has launched AidaBREAST, a multi-omic assay designed to assess locoregional recurrence risk and potential benefits of radiation therapy for early-stage invasive breast cancer. This innovation, built on the Akoya PhenoImager HT platform, aims to provide comprehensive tumor biology insights. Despite the significant product launch, Quanterix faces financial challenges with a moderate GF Score™ of 66/100, low profitability, and its stock trading near a 10-year low.
Quanterix, PreludeDX highlights AidaBREAST multi-omic assay
Quanterix and PreludeDX have highlighted AidaBREAST, a new multi-omic assay designed to predict locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer. Developed on the Akoya PhenoImager HT platform, the assay leverages spatial biology and AI to provide insights into tumor biology. This tool offers clinicians a unique capability to inform treatment decisions by predicting both recurrence likelihood and the efficacy of radiation therapy for specific patients.
Quanterix (QTRX) to Launch Content Innovation Engine at AACR Ann
Quanterix Corporation announced it will launch its Content Innovation Engine at the 2026 AACR Annual Meeting, integrating Akoya Biosciences' spatial biology platform with its own ultra-sensitive immunoassay technology. This tool aims to provide researchers with a systematic method for extracting deeper insights from tissue samples in cancer research. Despite insider buying activity, Quanterix faces challenges in profitability and its GF Score™ of 65 indicates moderate potential for long-term returns with noted weaknesses.
New Quanterix platform is built to move cancer biology toward the clinic
Quanterix Corporation is set to unveil its Content Innovation Engine at the AACR Annual Meeting 2026. This new platform integrates Akoya Biosciences' spatial biology technology with Quanterix's immunoassay development expertise, aiming to accelerate cancer research from discovery to clinical application. The company will also introduce new modules and kits, like the IO60 Spike-In Module and PhenoCode Molecular Barcoding Kit, designed to enhance the understanding of cancer biology and immunotherapy.
Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates
Quanterix Corporation (QTRX) announced its financial results for the second quarter, reporting a loss per share of $0.38, which was wider than the Zacks Consensus Estimate of a $0.22 loss and the previous year's loss of $0.18. The company also missed revenue expectations, with total sales of $22.65 million falling short of the consensus estimate by 2.22% and showing a slight decrease from the $22.7 million reported in the prior-year quarter.
Aberdeen Group plc Trims Stock Holdings in Quanterix Corporation $QTRX
Aberdeen Group plc significantly reduced its stake in Quanterix Corporation by 81.6% in the fourth quarter, selling over 460,000 shares but still retaining a holding worth about $662,000. While many institutional investors increased their positions, Quanterix's stock is trading near its 1-year low, and analysts maintain a "Reduce" rating with an $8 target, noting a Q4 EPS miss despite a revenue beat. The company, which specializes in ultra-sensitive digital immunoassay platforms, has 86.48% institutional ownership.
Quanterix (QTRX) Executive Chair receives 6,178-share stock grant
Quanterix Corp's Executive Chair, William P. Donnelly, received a grant of 6,178 shares of common stock. These shares were awarded at $0.00 per share as compensation for his service on the Board of Directors and its committees during the first quarter of 2026, rather than being an open-market purchase. Following this transaction, Donnelly directly holds a total of 154,127 shares of Quanterix Common Stock.
Quanterix (QTRX) director awarded 4,310 shares for board service
Quanterix (QTRX) director Scott Mendel was granted 4,310 shares of common stock as compensation for his service on the company's Board of Directors and its committees for the first quarter of 2026. These shares were awarded in lieu of cash fees, and following this transaction, Mendel directly holds 12,527 shares. The filing was submitted on SEC Form 4, which provides transparency regarding insider transactions.
Quanterix (QTRX) COO gains stock via RSU vesting with tax withholding
Quanterix Corp's Chief Operating Officer, Michael Francis Miller, converted 229 restricted stock units into common shares on March 31, 2026. To cover tax obligations, 69 shares were withheld at $3.52 per share, resulting in a net increase of 160 common shares. Following these transactions, Miller directly holds 31,431 shares of Quanterix common stock.
QTRX: Alzheimer’s Blood Test Advancements Will Drive Strong Long Term Upside
Quanterix (QTRX) has made significant advancements in Alzheimer's blood testing, including submitting a multi-analyte algorithmic blood test to the FDA and partnering to offer non-invasive biomarker tests nationally. Despite a modest adjustment to its price target reflecting slightly lower revenue and profit margin assumptions, the company's valuation remains stable at a Fair Value of $7.33. These developments, alongside new CEO appointment and promising 2026 revenue guidance, position Quanterix for strong long-term growth in the biomarker diagnostics market.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart | Capital.com Australia
Capital.com Australia provides a stock price quote and current price chart for Quanterix Corp (QTRX). The platform offers online trading services through its smart investment app.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart
This article provides a current stock price quote and chart for Quanterix Corp (QTRX), highlighting its intraday performance, key stats, and trading conditions on Capital.com. It details CFD trading information, including spreads, overnight funding adjustments, and margin requirements. The page also includes related share articles for other companies and customer reviews for the trading platform.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart
This article provides the current stock price and chart for Quanterix Corp (QTRX), along with key trading conditions and financial statistics. It highlights QTRX's current price of 3.75, an increase of 9.97%, and details CFD trading information such as spread, overnight funding adjustments, and margin requirements. The page also includes related share articles and customer reviews for the Capital.com platform.
Quanterix Corp (QTRX) Stock Price Quote Today & Current Price Chart
The article provides a title for Quanterix Corp (QTRX) stock price quote and current price chart, indicating financial information. It also mentions "Online Trading with Smart Investment App" from Capital.com, suggesting a trading platform context.
Quanterix Corporation Schedules 2026 Annual Meeting of Stockholders for June 15
Quanterix Corporation has announced that its 2026 Annual Meeting of Stockholders will be held on June 15, 2026. The announcement was made on March 27, 2026, and the meeting will cover corporate matters and provide updates on the company's performance and future plans. Quanterix is known for its high-definition biomarker detection technology and regularly engages with stakeholders through these meetings.
